Aura Biosciences, Inc. (AURA)Healthcare | Biotechnology | Boston, United States | NasdaqGM
7.00 USD
+0.16
(2.339%)
⇧
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:23 a.m. EDT
The investment case for Aura Biosciences is fundamentally broken. The company is trapped in a multi-year death spiral, having lost more than half its value over the last three years with no recovery in sight. Fundamentals are dire: the business is burning cash aggressively, generating negative free cash flow, and posting double-digit losses on both assets and equity. The balance sheet, while currently showing low debt relative to equity, is propped up by a massive cash pile that is being consumed by operations, leaving no runway for sustainable growth. The recent capital raise is a desperate attempt to stay alive, not a sign of confidence. Technically, the stock is in a confirmed downtrend, trading below its 50-day moving average despite a slight bounce off the lows. The statistical forecast model offers no help, predicting a flat-to-negative move with very low confidence, which aligns with the lack of any positive catalyst. Most damning is the options flow: traders are not buying calls; they are buying deep out-of-the-money puts as insurance against further collapse. This speculative positioning confirms that the smart money sees only risk here. With no dividend to cushion the blow and a deteriorating business model, this is a security to avoid entirely. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.126488 |
| MSTL | 0.150897 |
| AutoETS | 0.153829 |
| AutoARIMA | 0.153845 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 6.95 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.671 |
| Excess Kurtosis | -0.63 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 15.843 |
| Market Cap | 724,054,912 |
| Forward P/E | -3.45 |
| Beta | 0.40 |
| Website | https://www.aurabiosciences.com |
As of July 11, 2026, 6:23 a.m. EDT: Speculators are overwhelmingly positioning for downside protection, evidenced by massive open interest in out-of-the-money puts compared to negligible call activity. The put/call ratio is heavily skewed toward expiration, with significant volume concentrated in strikes well below the current price, indicating a consensus expectation of continued weakness or a 'crash' scenario rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.067073226 |
| Address1 | 80 Guest Street |
| Address2 | 5th Floor |
| All Time High | 26.16 |
| All Time Low | 4.345 |
| Ask | 8.6 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 771,340 |
| Average Daily Volume3 Month | 655,995 |
| Average Volume | 655,995 |
| Average Volume10Days | 771,340 |
| Beta | 0.395 |
| Bid | 5.07 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 1.672 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.0 |
| Current Ratio | 7.093 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 7.05 |
| Day Low | 6.55 |
| Debt To Equity | 15.843 |
| Display Name | Aura Biosciences |
| Earnings Timestamp | 1,778,529,600 |
| Earnings Timestamp End | 1,778,529,600 |
| Earnings Timestamp Start | 1,778,529,600 |
| Ebitda | -117,510,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -5.327 |
| Enterprise Value | 625,963,904 |
| Eps Forward | -2.03 |
| Eps Trailing Twelve Months | -1.71 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.2152 |
| Fifty Day Average Change | -0.21519995 |
| Fifty Day Average Change Percent | -0.029825917 |
| Fifty Two Week Change Percent | 6.7073226 |
| Fifty Two Week High | 9.535 |
| Fifty Two Week High Change | -2.5349998 |
| Fifty Two Week High Change Percent | -0.2658626 |
| Fifty Two Week Low | 4.73 |
| Fifty Two Week Low Change | 2.27 |
| Fifty Two Week Low Change Percent | 0.47991544 |
| Fifty Two Week Range | 4.73 - 9.535 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,635,514,200,000 |
| Float Shares | 93,302,233 |
| Forward Eps | -2.03 |
| Forward P E | -3.4482758 |
| Free Cashflow | -51,558,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 113 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01155 |
| Held Percent Institutions | 0.4936 |
| Implied Shares Outstanding | 103,436,416 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-10-29 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts. |
| Long Name | Aura Biosciences, Inc. |
| Market | us_market |
| Market Cap | 724,054,912 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_100249028 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -112,393,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 723,020,547 |
| Number Of Analyst Opinions | 5 |
| Open | 6.73 |
| Operating Cashflow | -91,280,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 617 500 8864 |
| Pre Market Change | -0.17000008 |
| Pre Market Change Percent | -2.4285724 |
| Pre Market Price | 6.83 |
| Pre Market Time | 1,784,029,966 |
| Previous Close | 6.84 |
| Price Hint | 2 |
| Price To Book | 4.1866026 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.868 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.16 |
| Regular Market Change Percent | 2.33918 |
| Regular Market Day High | 7.05 |
| Regular Market Day Low | 6.55 |
| Regular Market Day Range | 6.55 - 7.05 |
| Regular Market Open | 6.73 |
| Regular Market Previous Close | 6.84 |
| Regular Market Price | 7.0 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 593,731 |
| Return On Assets | -0.50593 |
| Return On Equity | -0.95567 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 103,436,416 |
| Shares Percent Shares Out | 0.067 |
| Shares Short | 6,932,229 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 3,762,979 |
| Short Name | Aura Biosciences, Inc. |
| Short Percent Of Float | 0.0675 |
| Short Ratio | 10.89 |
| Source Interval | 15 |
| State | MA |
| Symbol | AURA |
| Target High Price | 24.0 |
| Target Low Price | 15.0 |
| Target Mean Price | 18.8 |
| Target Median Price | 17.0 |
| Total Cash | 114,733,000 |
| Total Cash Per Share | 1.11 |
| Total Debt | 16,991,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.71 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.30465 |
| Two Hundred Day Average Change | 0.69535017 |
| Two Hundred Day Average Change Percent | 0.11029164 |
| Type Disp | Equity |
| Volume | 593,731 |
| Website | https://www.aurabiosciences.com |
| Zip | 2,135 |